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SUMMARY
Introduction Pseudoachondroplasia (PSACH) is an autosomal dominant osteochondrodysplasia due 
to mutations in the gene encoding cartilage oligomeric matrix protein. It is characterized by rhizomelic 
dwarfism, limb and vertebral deformity, joint laxity and early onset osteoarthrosis. We present the girl 
with the early expressed and severe PSACH born to clinically and radiographically unaffected parents.
Case Outline A 6.5-year-old girl presented with short-limbed dwarfism (body height 79.5 cm, <P5; -32%) 
and normal craniofacial appearance and intelligence. The girl was normal until 3 months of age when 
she expressed growth retardation with apparently shorter extremities in relation to the torso. With age, 
her rhizomelic dwarfism became increasingly visible, and since completed 15 months of age, when 
she started to walk, the disease was complicated with genu varum, lumbar lordosis and abnormal gait. 
Beside visibly short forearms, short, broad and ulnar deviation of the hands, brachydactyly and joint 
hyperlaxity, the radiographic picture showed markedly flared metaphyses, small and irregular epiphyses 
and poorly formed acetabulum.
Conclusion PSACH is an achondroplasia-like rhizomelic dwarfism recognized by the absence of abnor-
mality at birth, normal craniofacial appearance, characteristic epiphyseal and metaphyseal radiographic 
finding and joint hyperlaxity.
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INTRODUCTION
Pseudoachondroplasia (PSACH) is a form 
of osteochondrodysplasia with an estimated 
prevalence of approximately 1/20,000-1/30,000 
individuals [1-4]. The basis of the disease forms 
an autosomal dominant defect in the expression 
of cartilage oligomeric matrix protein (COMP) 
caused by a structural mutation in exons 8-19 
of COMP gene located on the chromosome 
19p12-13.1 [5-8]. The majority of COMP muta-
tions are missense mutations and small in-frame 
deletions and duplications found in exons 8-14 
of this gene encoding the eight calmodulin-like 
calcium-binding repeats and exons 15-19 en-
coding the carboxyl-terminal globular domain 
[9]. The consequence of this defect, character-
ized by penetrance, is a development of the 
osteogenic disorder, i.e. the transformation of 
cartilage into bone tissue followed by typical 
metaphyseal, epiphyseal and vertebral abnor-
malities [1, 10]. The main clinical characteris-
tics of the disease are a disproportionate short 
stature similar to achondroplasia, brachydactyly, 
short, broad and ulnar deviation of the hands, 
forearms and lower limbs anomalies, joint hy-
perlaxity, abnormal gait, lumbar lordosis, scolio-
sis and early onset osteoarthrosis [1, 7-10]. The 
affected individual has normal length at birth, 
and generally, growth retardation will not be 
recognized until late infancy or more frequently 
between two to three years of age [7-10]. No-
tably, all patients have normal craniofacial ap-
pearance and intelligence [2, 10, 11]. Here, we 
present a girl with an early expressed and severe 
PSACH born to clinically and radiographically 
unaffected parents.
CASE REPORT
A 6.5-year-old girl presented with dispropor-
tionate short stature (79.5 cm, <P5; -32% from 
the average height for the age and gender), short 
and genu varum lower limbs, abnormal gait, 
exaggerated lumbar lordosis, short forearms, 
short, broad and ulnar deviation of the hands, 
brachydactyly and joint hyperlaxity (Figure 1). 
Craniofacial appearance and intelligence as well 
all other physical findings were normal.
She was born to clinically and radiographi-
cally unaffected and non-consanguineous par-
ents 5.5 years after her healthy brother aged 12 
years. Her birth weight was 2700 g, length 51 
cm and head circumference (HC) 33 cm. Ac-
cording to her parents, the girl was normal un-
til 3 months of age when she expressed growth 
retardation with apparently shorter extremi-
ties in relation to the torso. At 6 months of age 
her body length (BL) was 57 cm (-19%), body 
weight (BW) 6960 g and HC 43 cm. Achondro-
plasia was suspected, and then rachitis, based 
on bowl-like metaphysis and poorly formed 
epiphysis. With age, rhizomelic (short-limbed) 
dwarfism became increasingly apparent, and 
since completed 15 months of age, when she      
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started to walk, the disease was complicated with the genu 
valgum plus lumbar lordosis and abnormal gait. With age, 
her longitudinal growth showed the following values: at 17 
months 61 cm (-28.5%), at 25 months 65 cm (-29%) and 
at 4 years 75 cm (-26%). Having in mind a progressive and 
diagnostically unclear disorder, the child was referred to 
our institution for additional investigations.
Based on the abovementioned facts, as well as the char-
acteristic radiographic findings, the diagnosis of PSACH 
was verified (Figures 2A and 2B). The evident signs of 
osteoarthritis were not seen. Except for decreased serum 
concentration of 25(OH)D (64 nmol/L) and increased 
PTH (91.5 pg/ml) at first examination, all other labora-
tory findings, also including serum calcium, phosphorus 
and alkaline phosphatase, were normal. With 400 IU of 
vitamin D and additional intake of milk and milk products, 
the serum levels of 25(OH)D and PTH were normalized 
after 3 months. In order to maintain a normal balance of 
calcium and phosphorus, other than daily consumption 
of about 500 ml of milk or yogurt, the intake of vitamin 
D, 400 IU and 200 IU daily during colder and warmer 
weather periods, respectively, was recommended. Besides 
the corresponding paediatric and orthopaedic follow-up 
and adequate physical therapy, the parents were advised 
not to expose their child to exaggerated physical activities.
DISCUSSION
PSACH is a part of osteochondrodysplasias, a group of 
more than 150 distinct disorders characterized by bone 
and cartilage maldevelopment [2, 10]. In almost all of pa-
tients, it appears to be secondary to autosomal dominant 
structural mutation within the genes encoding for COMP 
on the chromosome 19p12-13.1, and is most closely related 
to multiple epiphyseal dysplasia (MED/EDM1), a disorder 
also characterized by the mutation of the COMP [7-12].
COMP, also known as thrombospondin 5, is a 757-ami-
no acid or 550 k-Da homopentameric glycoprotein present 
in the extracellular matrix (ECM) of cartilage, tendon, liga-
ment and smooth muscle [13, 14]. Its presence in the ECM 
of these tissues is of essential significance for their growth, 
development and maintenance. As the consequence of this 
defect, both PSACH and MED chondrocytes retain lamel-
lar and granular appearing material in large rough endo-
plasmic reticulum cisternae [11]. This material is com-
posed of COMP and other ECM proteins including types 
II and IX collagens and matrilin-3 [15, 16]. By the method 
of fluorescence deconvolution analysis, these retained pro-
teins have been recently shown to be organized into the 
matrix network suggesting that the stalled mutant COMP 
inappropriately interacts intracellularly with the matrix 
protein partners [15, 16, 17]. The retention of the intra-
cellular matrix is toxic to the chondrocytes, and induces 
apoptosis causing the chondrocyte death [17]. The loss 
of chondrocytes in the growth plate translates, resulting 
into decreased long bone growth and the disproportion-
ate short stature in PSACH. Additionally, the intracellular 
retention of the COMP and death of chondrocytes result in 
loss of these proteins in the ECM [18, 19, 20]. The respec-
tive consequence is a disorganized type II collagen network 
most likely due to the absence of type IX collagen which is 
needed to crosslink type II collagen [21]. Association of the 
COMP deficit in the ECM and poorly organized structure 
of the articular cartilage lead to joint abnormalities and 
early onset osteoarthritis in patients with the PSACH and 
MED/EDM1 [20, 22].
The children with PSACH are always normal at birth 
and its disease usually presents at 2-3 years of age with 
disturbance in walking and lower limb deformity [7-11]. 
Over the years, rhizomelic dwarfism becomes apparent 
Figure 1. Our patient with PSACH
Figure 2. Radiographic finding of our patients with PSACH: A) Lateral 
thoracolumbar radiograph showing platyspondyly with the anterior 
tongue-like protrusion of the upper lumbar and lower thoracic ver-
tebrae; B) Anteroposterior radiograph of pelvis and lower extremity 
showing poorly formed acetabulum, large metaphyses, irregular epi-
physes and marked bowing of the long bones.
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with progressively increasing morbidity, especially second-
ary osteoarthritic changes [7-10]. The adult height ranges 
from 82 to 130 cm with a mean height of approximately 
118 cm [7, 10]. Physical examination reveals normal facies 
and intelligence [10, 11].
The radiographic features are typical for rhizomelic 
dwarfism and include shortened bones, more prominent 
in the proximal than in the distal part, with flared and ir-
regular metaphysis and small and poorly formed epiphy-
ses [10, 23]. The most affected long bones are femur and 
humerus. The bones of the hand and foot are too broad 
and short with a small and immature epiphysis [23]. The 
x-ray of the pelvis shows flattened, irregular femoral heads 
with shortened necks and widened pubic symphysis [7]. 
The acetabulum is poorly formed with the horizontal roofs. 
The radiographic features include normal skull and facial 
bones and variable vertebral findings such as platyspondyly 
with the anterior beaking of the upper lumbar and lower 
thoracic vertebrae, lordosis and scoliosis [8, 23]. Differen-
tial diagnoses of this radiographic picture in the context of 
clinical findings include achondroplasia, MED/EDM1 and 
spondyloepiphyseal dysplasia (SED) congenita [9]. Patients 
with achondroplasia have disproportionally large head with 
a prominent frontal region and depressed bridge of the 
nose. The basic differentiating point is that the epiphyses 
of patients with achondroplasia are normal. MED/EDM1 is 
characterized by a near normal pelvis with some scalloping 
of the acetabular margin. The SED, contrary to PSACH, is 
typified by hip joints that are affected disproportionately 
in relation to more distal portion of the lower extremities.
The diagnosis of PSACH is based primarily on personal 
and family history and characteristic physical and radio-
graphic findings [10, 24, 25]. The finding of decreased se-
rum COMP concentration may be an additional diagnostic 
marker of PSACH [4, 7, 26]. Whenever possible, genetic 
verification of the disorder is also done [25].
Therapy of PSACH is reduced to physiotherapy, man-
agement of spinal deformities and corrective orthopaedic 
surgery [25, 27, 28, 29]. Intensive physical activity is recom-
mended. Surgical correction of the limb deformities should 
be postponed until the end of the growth period [28].
We are presenting a girl who is a typical example of the 
patient with PSACH. She was born with a normal BL and 
her appearance was the same as that of any other child with 
clinically and radiographically unaffected parents. Beside 
her, the parents have a healthy 12-year old boy. Mode of 
PSACH inheritance clearly compels us to draw the conclu-
sion that, in our patient, the disease was the result of newly 
developed mutation. As the realistic possibility of somatic 
mutation in the early postconception phase is low, it can 
be additionally concluded that the cause of PSACH devel-
opment in this case should be searched in the germline 
(gonadal) mosaicism of parents [25, 30].
Although PSACH is not generally recognized until late 
infancy or more frequently between two to three years of 
age, progressive longitudinal growth retardation of the 
extremities, as the initial illness sign, was detected in our 
patient already at age of 5 months [7-10]. In her later years, 
her disease also manifested other clinical and radiological 
characteristics, which represented the basis of her diag-
nostics [10, 24, 25].
Having in mind the age of our patient, as well as the 
severity of the disease at this stage, treatment was based 
on adequate paediatric-orthopaedic supervision, physio-
therapy and avoiding of intensive physical activity [25, 28]. 
A suboptimal serum level of 25(OH)D recorded at first 
examination was corrected. Because of the significance of 
vitamin D in the calcium and phosphorus homeostasis, as 
well as the bone tissue itself, the maintenance of vitamin 
D optimal balance with adequate diet regime should be 
continued.
In conclusion, PSACH represents a rare form of achon-
droplasia-like rhizomelic dwarfism recognized by the 
absence of abnormality at birth, normal craniofacial ap-
pearance, characteristic epiphyseal and metaphyseal radio-
graphic findings and joint hyperlaxity. Despite being the 
AD inherited disorder, it is usually seen as the consequence 
of a newly developed mutation, i.e. gonadal mosaicism in 
parents. Therapy is primarily physical-orthopaedic. In ad-
dition, the prevention of vitamin D and/or calcium deficit 
is of exceptional significance, identically to other disorders 
that can disturb the integrity of bone tissue.
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КРАТАК САДРЖАЈ
Увод Псе  у  до  а  хон  дро  пла  зи  ја (ПСАХ) је ауто  зом  но до  ми  нант-
на осте  о  хон  дро  ди  спла  зи  ја иза  зва  на му  та  ци  јом ге  на ко  ји ко-
ди  ра хр  ска  ви  ча  ви оли  го  мер  ни ма  трик  сни про  те  ин. Од  ли  ку-
ју је ри  зо  ме  лич  ни ма  ли раст, де  фор  ми  те  ти екс  тре  ми  те  та и 
кич  ме  ног сту  ба, хи  пе  ре  ла  стич  ност згло  бо  ва и ра  на осте  о-
ар  тро  за. Сле  ди при  каз де  вој  чи  це кли  нич  ки и ра  ди  о  граф  ски 
здра  вих ро  ди  те  ља с те  шком и ра  но ис  по  ље  ном ПСАХ.
При  каз бо  ле  сни  ка Де  вој  чи  ца уз  ра  ста од шест и по го  ди  на, 
нор  мал  ног кра  ни  о  фа  ци  јал  ног из  гле  да и ин  те  ли  ген  ци  је, при-
мље  на је на пре  глед због дис  про  пор  ци  о  нал  но ма  лог ра  ста 
(те  ле  сна ви  си  на 79,5 cm; <П5; -32%). За  о  ста  ја  ње у лон  ги  ту  ди-
нал  ном ра  сту са вид  но кра  ћим екс  тре  ми  те  ти  ма у од  но  су на 
труп уоче  но је три ме  се  ца по ро  ђе  њу. Са ра  стом и раз  во  јем 
ри  зо  ме  лич  ни тип ни  ског ра  ста по  ста  јао је све из  ра  же  ни  ји, а 
од на  вр  ше  них 15 ме  се  ци, ка  да је про  хо  да  ла, бо  лест се ком-
пли  ко  ва  ла са ге  на ва  ра, лум  бал  ном лор  до  зом и оте  жа  ним 
хо  да  њем. По  ред упа  дљи  во скра  ће  них над  лак  ти  ца, кра  ћих, 
ши  ро  ких и ул  нар  но де  ви  ра  них ша  ка, крат  ких пр  сти  ју и хи-
пе  ре  ле  стич  них згло  бо  ва, на ренд  ген  ским сним  ци  ма су за-
па  же  ни на  гла  ше  но ра  све  тље  не ме  та  фи  зе, ма  ле не  пра  вил  не 
епи  фи  зе и сла  бо фор  ми  ра  ни аце  та  бу  лу  ми.
За  кљу  чак ПСАХ је об  лик ри  зо  ме  лич  ног ма  лог ра  ста на  лик 
на ахон  дро  пла  зи  ју, пре  по  зна  тљи  ву по нор  мал  ним из  гле  дом 
на ро  ђе  њу, не  по  сто  ја  њем кра  ни  о  фа  ци  јал  них по  ре  ме  ћа  ја, 
ти  пич  ним епи  фи  зо  ме  та  фи  зар  ним ра  ди  о  граф  ским на  ла  зом 
и хи  пе  ре  ла  стич  но  шћу згло  бо  ва.
Кључ  не ре  чи: псе  у  до  а  хон  дро  пла  зи  ја; ри  зо  ме  лич  ни ма  ли 
раст; осте  о  хон  дро  ди  спла  зи  је
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